A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)

NCT00110435 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1229

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus
Hypercholesterolemia

Interventions

DRUG: MK0653A, ezetimibe (+) simvastatin
DRUG: Duration of Treatment: 4 wk placebo run in then 6 wk active
DRUG: Comparator: atorvastatin

Sponsor

Organon and Co